Identifying opportunities for expanding SAMBA use to Faith-based and other organisations supporting HIV monitoring in treatment programmes in Sub-Saharan Africa and Eastern Europe

确定将 SAMBA 的使用范围扩大到信仰组织和其他支持撒哈拉以南非洲和东欧治疗项目中艾滋病毒监测的组织的机会

• 批准号: 104103
• 金额: $ 6.37万
• 依托单位: DIAGNOSTICS FOR THE REAL WORLD (EUROPE) LIMITED
• 依托单位国家: 英国
• 项目类别: EU-Funded
• 财政年份: 2017
• 资助国家: 英国
• 起止时间: 2017 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=104103
• 关键词: Identifying; opportunities; expanding; SAMBA; use

"DRW has developed SAMBA, a nucleic acid test system that can be used at the point of care in rural, remote locations to test for HIV viral load for therapy monitoring and early HIV infection diagnosis in infants born from HIV+ mothers to allow for early treatment. SAMBA instrument and tests are CE-marked, allowing use in Europe and Africa. DRW needs to develop the market and is working with ministries of health in several African countries and a hospital in Ukraine to implement SAMBA. In Africa, challenges associated with governments are proving to be a slow and circuitous process. However, there are private organisations working on the ground and in need of appropriate tools to test for HIV in remote, decentralised settings. DRW is already working with Médecins Sans Frontières and this project proposes to identify and quantify additional opportunities in private health organisations, such as faith-based health providers and non-governmental organisations, while continuing to work with government organisations.An estimated 100,000 faith-based organisations (FBO) in Africa provide health care to the poor and vulnerable and may provide 20% of global HIV/AIDS work. In Uganda, FBOs provide \>25% of all health services and private non-for-profits (including FBOs) account for 41% of hospitals and 22% of lower level health facilities. These organisations are highly motivated to provide health care to people in critical need but who cannot afford it. DRW proposes to identify and engage with such organisations in African and Eastern European markets, which are currently inaccessible, and develop a business strategy for delivering SAMBA to those markets. The information gathered will be used to develop an appropriate and sustainable strategy for supplying tests to these organisations. The following information will be researched: a) identify countries, organisations and sites for subsequent implementation in 'Phase 2'; b) determine number of tests needed per year; c) determine price acceptability; d) understand test site environment, facilities and users; e) update market analysis including market size, funding mechanisms and sustainability f) update and expand DRW's commercialisation strategy based on project Phase 1 outcomes and g) if time and resources allow, perform trial implementation or training for SAMBA. Determining additional implementation channels in addition to large government programmes will expand the use of SAMBA, impacting more people's health and allowing DRW to exploit SAMBA beneficially, thereby supporting testing needs and creating a sustainable future for the company's work and the SAMBA product."

“DRW开发了SAMBA，这是一种核酸检测系统，可在农村、偏远地区的护理点使用，检测艾滋病毒病毒载量，用于艾滋病毒阳性母亲所生婴儿的治疗监测和早期艾滋病毒感染诊断，以便早期治疗。SAMBA仪器和测试获得CE认证，允许在欧洲和非洲使用。DRW需要开发市场，并正在与几个非洲国家的卫生部和乌克兰的一家医院合作实施SAMBA。在非洲，与政府有关的挑战被证明是一个缓慢而曲折的过程。然而，有一些私营组织在实地工作，需要适当的工具来在偏远、分散的环境中检测艾滋病毒。DRW已经与无国界医生组织合作，该项目建议确定和量化私人卫生组织（如信仰卫生提供者和非政府组织）的额外机会，同时继续与政府组织合作。在非洲，有1000个信仰组织（FBO）为穷人和弱势群体提供医疗保健，可能提供全球艾滋病毒/艾滋病工作的20%。在乌干达，FBO提供了所有卫生服务的25%，私营非营利组织（包括FBO）占医院的41%和较低水平卫生设施的22%。这些组织非常积极地为急需但负担不起医疗服务的人提供医疗服务，DRW建议在目前无法进入的非洲和东欧市场确定并与这些组织合作，并制定向这些市场提供SAMBA的商业战略。收集的信息将用于制定适当和可持续的战略，为这些组织提供测试。将研究以下信息：a）确定"第2阶段"后续实施的国家、组织和地点; B）确定每年所需的试验次数; c）确定价格可接受性; d）了解试验地点的环境、设施和用户; e）更新市场分析，包括市场规模，融资机制和可持续性f）根据项目第1阶段的成果更新和扩展DRW的商业化战略，g）如果时间和资源允许，为SAMBA进行试验实施或培训。除了大型政府项目外，确定其他实施渠道将扩大SAMBA的使用，影响更多人的健康，并使DRW能够有利地利用SAMBA，从而支持测试需求，并为公司的工作和SAMBA产品创造可持续的未来。"